X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Korean Company GenKOre Offering Genetic Base-Editing Tech

    Gene Silencing Alzheimers Drug, A World First, Shows Promise

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Australia Falling Short In Biotech Research Funding – Study

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Viral Infections Curbed By Gene Scissors In Human Cells

    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Korean Company GenKOre Offering Genetic Base-Editing Tech

    Gene Silencing Alzheimers Drug, A World First, Shows Promise

    As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

    Australia Falling Short In Biotech Research Funding – Study

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Viral Infections Curbed By Gene Scissors In Human Cells

    Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

    Neurodevelopmental Issue Leads To Testicular Cancer Risk

    Tumors Can Get Destroyed By Bacteria-Aid To Immune System

    Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

    The UK begins the biggest ever immunization program

    New Approach Brought By Singapore For Pneumococcal Vaccines

    New Gestational Diabetes Alliance By Birmingham University

    New Gestational Diabetes Alliance By Birmingham University

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    A first-class conference line-up announced ahead of Chemspec Europe 2023

    Omya enhances supply of active pharmaceutical ingredients

    Omya enhances supply of active pharmaceutical ingredients

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Gene Silencing Alzheimers Drug, A World First, Shows Promise

Content Team by Content Team
29th April 2023
in Drug Development, News
Korean Company GenKOre Offering Genetic Base-Editing Tech

UK scientists have gone on to conduct the first ever trial of a new drug for Alzheimer’s that is able to safely as well as successfully lower the levels of the very harmful tau protein, which is known to cause the disease.

The trial led by University College, London team represents the first time that a gene silencing form of approach has been adopted in dementia as well as Alzheimer’s disease.

This novel approach uses drug by name of BIIB080-IONIS-MAPTRx to silence gene coding in the case of the tau protein, also known as the microtubule-associated protein tau gene. All this prevents the gene from getting translated into the protein in a dose-dependent and reversible way. It also lowers the production of that particular protein and alters the course of the disease. One of the consultant neurologists from UCL Queen Square Institute of Neurology, Dr. Catherine Mummery, opined that they will have to put further research to gauge the extent to which the drug can slow the progression of the physical symptoms of the disease and analyse the drug in older as well as larger people groups and in a more diverse set of populations.

However, these results are a prominent step forward in assuring that one can successfully target tau through a gene silencing drug so as to slow or possibly even reverse Alzheimer’s disease and also other diseases that are caused by the accumulation of tau in the future, Mummery added.

It is well to be noted that the phase 1 trial too into account the safety of BIIB080 in terms of what it does to the body and how well it can go on to target the MAPT gene. 46 patients, with an average age of 66, were a part of the trial that happened from 2017 to 2020.

The trial took into account three doses of the drug given via an intrathecal injection that were compared with the placebo. The results that got published in the Nature Medicine journal demonstrated that the drug was pretty well tolerated, with all patients completing the entire treatment period and more than 90% completing the post-treatment schedule.

Apparently, patients in both the treatment and placebo groups got to have either mild or moderate side effects; the most common was a headache once the drug was injected. That said, no serious adverse events were seen among the patient group that was given the drug.

The research also paid attention to two variations of the tau protein within the central nervous system, which was a reliable disease indicator during the entire study period. Additional 50% reduction in levels of total tau as well as phosphor tau concentration within the CNS after 24 weeks were found in both treatment groups, which went on to receive the highest drug dosage.

Notably, there are currently no treatments that target tau. However, aducanumab, lecanemab that have been approved recently for usage in certain situations by the USFDA go on to target a different disease mechanism within AD, which is the amyloid plaque mechanism.

Previous Post

Australia Falling Short In Biotech Research Funding - Study

Related Posts

As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
Manufacturing

Australia Falling Short In Biotech Research Funding – Study

29th April 2023
Catalent acquires cell and gene therapy-focused MaSTherCell for $315m
Manufacturing

Viral Infections Curbed By Gene Scissors In Human Cells

29th April 2023
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

27th April 2023
DoKaSch Temperature Solutions and Japan Airlines sign Master Rental Agreement
News

United Cargo – after Opticooler RAP, now also Opticooler RKN certified

26th April 2023
The UK begins the biggest ever immunization program
News

New Approach Brought By Singapore For Pneumococcal Vaccines

26th April 2023

Latest News

Korean Company GenKOre Offering Genetic Base-Editing Tech
Drug Development

Gene Silencing Alzheimers Drug, A World First, Shows Promise

29th April 2023
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
Manufacturing

Australia Falling Short In Biotech Research Funding – Study

29th April 2023
Catalent acquires cell and gene therapy-focused MaSTherCell for $315m
Manufacturing

Viral Infections Curbed By Gene Scissors In Human Cells

29th April 2023
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment
News

Neurodevelopmental Issue Leads To Testicular Cancer Risk

27th April 2023
Tumors Can Get Destroyed By Bacteria-Aid To Immune System
Drug Development

Malaria Immunity Boosted By Matrix-M, Saponin Based Adjuvant

27th April 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In